Data / Form D filings / Bonum Therapeutics, Inc.
Bonum Therapeutics, Inc.: Form D filings
Bonum Therapeutics, Inc., a biotechnology company in Seattle, WA, filed 3 Form D notices with the SEC between 2021 and 2026. The latest, on April 17, 2026, reports $26.9 million sold of a $32.3 million offering to 8 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 1150 EASTLAKE AVENUE E SUITE 1100, Seattle, WA, 98109
- Phone
- (206) 888-8485
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Year incorporated
- 2021
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1898714
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Apr 17, 2026 | New notice | $32,301,381 | $26,907,396 | $5,393,985 | 8 | Apr 3, 2026 | sec.gov |
| Nov 29, 2022 | New notice | $93,041,420 | $45,041,421 | $47,999,999 | 10 | Nov 15, 2022 | sec.gov |
| Dec 22, 2021 | New notice | $3,560,661 | $1,186,887 | $2,373,774 | 5 | Dec 8, 2021 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| John Mulligan | Executive Officer, Director, Promoter | |
| John McKearn | Director | |
| Monique Schiersing | Director | |
| Nicholas Walrod | Director | |
| Karl Handelsman | Director | |
| Diane Hollenbaugh | Executive Officer | |
| Neela Patel | Executive Officer | |
| Mitchell Mutz | Director | |
| Samuel Bjork | Director | |
| Gaurav Aggarwal | Director | |
| Samuel Blackman | Director |
Other biotechnology companies in Washington that filed recently
- Key Proteo, Inc. $2.3 million · Oct 23, 2026
- Inmedix, Inc. $4 million · Oct 22, 2026
- Q-Immune, Inc. $25,000 · Sep 28, 2026
- Hexamer Therapeutics, Inc $500,000 · Sep 15, 2026
- MalarVx, Inc. $125,000 · Aug 25, 2026
- Strella Biotechnology, Inc. $1.8 million · Aug 14, 2026
Every Form D from the week of Apr 13, 2026 · All recent filings in Washington · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Bonum Therapeutics, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.